Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.73 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 2/20 | 0.46 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.44 |
| ▸ | CDK2 | P24941 | 4/20 | 0.44 |
| ▸ | KIF20A | O95235 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL367606 | 0.86 | MAP2K1 (0.62) | MAP2K1CNR2ADORA2AMTNR1ACYP2D6 | |
| SCHEMBL29526844 | 0.84 | MAP2K1 (1.00) | MAP2K1CNR2ADORA2AMTNR1AKMT2A | |
| SCHEMBL13325426 | 0.84 | MAP2K1 (0.68) | MAP2K1CNR2ADORA2AMTNR1ACYP2D6 | |
| SCHEMBL1607007 | 0.84 | MAP2K1 (1.00) | MAP2K1CNR2ADORA2AMTNR1AKMT2A | |
| Methoxymethane SCHEMBL28146835 | 0.84 | MAP2K1 (0.77) | MAP2K1CNR2ADORA2AMTNR1ACYP2D6 | |
| SCHEMBL1474975 | 0.83 | MAP2K1 (0.65) | MAP2K1CNR2ADORA2AMTNR1ACYP2D6 | |
| SCHEMBL30368631 | 0.82 | MAP2K1 (0.64) | MAP2K1CNR2ADORA2AMTNR1ACYP2D6 | |
| Potassium Ion SCHEMBL2688784 | 0.81 | MAP2K1 (0.63) | MAP2K1CNR2ADORA2AMTNR1ACYP2D6 | |
| Potassium Ion SCHEMBL29688228 | 0.81 | MAP2K1 (0.63) | MAP2K1CNR2ADORA2AMTNR1ACYP2D6 | |
| SCHEMBL1867330 | 0.81 | MAP2K1 (0.63) | MAP2K1CNR2ADORA2AMTNR1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | VIIV HEALTHCARE UK (NO. 4) LIMITED | 2022-06-28 | — | — | US | disclosed |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2021-01-28 | — | — | US | disclosed |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2020-02-13 | — | — | US | disclosed |
| US-20190111066-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2019-04-18 | — | — | US | disclosed |
| US-20180000849-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2018-01-04 | — | — | US | disclosed |
| US-20160361328-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160361328-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20150315218-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-11-05 | — | — | US | disclosed |
| US-9169251-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2015-10-27 | — | — | US | disclosed |
| US-20150232414-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| US-20090176806-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | ZHANG HAN-CHENG | 2009-07-09 | — | — | US | disclosed |
| US-20090176806-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | ZHANG HAN-CHENG | 2009-07-09 | — | — | US | disclosed |
| US-7524858-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-28 | — | — | US | disclosed |
| US-7524858-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-28 | — | — | US | disclosed |
| US-20080312230-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| EP-1506192-B1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-27 | — | — | EP | disclosed |
| EP-1725569-B1 | PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1761529-B1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2007-11-14 | — | — | EP | disclosed |
| US-20030181463-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000849-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | MAP2K1 2634/4885CNR2 305/4885ADORA2A 2152/4885 |
| US-20150315218-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | ZC3HAV1L, CCR5, CCRL2 | MAP2K1 2455/4885CNR2 464/4885ADORA2A 2214/4885 |
| US-20190111066-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | MAP2K1 2634/4885CNR2 305/4885ADORA2A 2152/4885 |
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | CCR1, CCL2, CCL11 | MAP2K1 1708/4885CNR2 224/4885ADORA2A 419/4885 |
| US-20090176806-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | PRKDC, PRKACA, MAP3K20 | MAP2K1 389/4885CNR2 4089/4885ADORA2A 4370/4885 |
| US-20150232414-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | MAP2K1 2634/4885CNR2 305/4885ADORA2A 2152/4885 |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | ZC3HAV1L, CCR5, CCRL2 | MAP2K1 2632/4885CNR2 338/4885ADORA2A 2255/4885 |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | CCR5, ZC3HAV1L, CCRL2 | MAP2K1 2634/4885CNR2 305/4885ADORA2A 2152/4885 |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | MAP2K1 2634/4885CNR2 305/4885ADORA2A 2152/4885 |
| US-20080312230-A1 | Organic Compounds | OPRM1, OPRL1, OPRD1 | MAP2K1 4448/4885CNR2 78/4885ADORA2A 2299/4885 |
| US-20160361328-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | MAP2K1 2634/4885CNR2 305/4885ADORA2A 2152/4885 |
| US-20030181463-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | MAP2K1 3885/4885CNR2 4587/4885ADORA2A 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.